![ADC Therapeutics SA logo](/logos/ADCT.webp)
ADC Therapeutics SA
NYSE:ADCT
Overview | Financials
Company Name | ADC Therapeutics SA |
Symbol | ADCT |
Currency | USD |
Price | 2.7 |
Market Cap | 260,948,250 |
Dividend Yield | 0% |
52-week-range | 0.36 - 6.04 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Ameet Mallik M.B.A., M.S. |
Website | https://www.adctherapeutics.com |
An error occurred while fetching data.
About ADC Therapeutics SA
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD